Telangana Drug Authority Seizes Illegal Cardiac Stimulant Injections Sold to Gym-Goers
The Telangana Drugs Control Administration seized 38 vials of Mephentermine Sulphate injections from an unlicensed premises in Warangal on June 9, 2026, after discovering they were being illegally sold to gym-goers for performance enhancement. Mephentermine Sulphate is a cardiac stimulant legitimately used in medical settings to treat low blood pressure during surgery, but requires strict medical supervision. The DCA warned that misuse of the drug by bodybuilders and athletes can cause serious cardiovascular disorders and potentially fatal complications.
The Telangana Drugs Control Administration (DCA) conducted a raid at an unlicensed premises in Charbouli, Warangal, on June 9, 2026, following a tip from the Warangal Police Commissioner's Task Force. Officials seized 38 vials of Termin Injection (Mephentermine Sulphate 30 mg/ml) from Mohammed Abdul Sohaib, who was allegedly stocking and supplying the drug illegally to gym enthusiasts. Mephentermine Sulphate is a legitimate cardiac stimulant used medically to treat low blood pressure by increasing noradrenaline release and improving cardiac output, but it must be administered only under medical supervision with dosages determined by a doctor. The DCA noted that the drug is increasingly being misused by bodybuilders and athletes seeking performance enhancement and endurance gains. Authorities warned that abuse of the injection carries serious risks, including cardiovascular disorders and potentially fatal consequences.
What different sources said
- The HinduCenter
Telangana DCA seizes cardiac stimulant injections being sold to gym-goers in Warangal
Related
Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.